Among the two biomarkers, ATF4 exhibited superior diagnostic accuracy, characterized by high sensitivity and specificity, highlighting its potential utility as a non-invasive screening biomarker for early MASLD detection. Here, ATF4 is linked to metabolic dysfunction-associated steatotic liver disease.